Elisa Roldan

[Vincent Rajkumar @VincentRK]

Just in: Good news for the myeloma field.

FDA approves teclistamab plus daratumumab (Tec-Dara) combination for myeloma for patients who have had at least one prior line of therapy.
Note: Always use Tec-Dara with monthly IVIG. It’s not optional.

That was fast! And this is unprecedented curve is why.

[Vincent Rajkumar @VincentRK]

Just out in the New England Journal of Medicine!

Our comprehensive Review on MGUS: Monoclonal Gammopathy of Undetermined Significance @NEJM https://t.co/7dza0YrFh5

5% of people over age 50 have MGUS. Every physician needs to know and understand MGUS. Lots of Tables and Figures. Bookmark!

How to test and manage patients. Who needs bone marrow exams and scans. It’s all in here!

MGUS is important not just because it’s a precursor to multiple myeloma. It causes a lot of other problems. Learn all about MGUS, and the various terms you hear MGCS, MGRS etc. in this Review

@myelomaMD and I have tried to keep every sentence in this Review simple and easy to follow. #MGUSVR

[Ben Derman @bdermanmd]

What's going to be different with the new IMWG response criteria?
Main changes:
- FLC >=10 mg/dL with abnormal ratio takes precedence over urine (but urine is not gone)
- No more sCR
- Bone marrow to confirm CR can be performed +/- 6 weeks from blood testing.
- 24-hour urine at baseline, and if M-protein present, retest only to confirm CR
- Patients can be considered to have PD if they meet criteria by a variable not considered measurable at baseline (major weakness with current response criteria is that it misses light chain escape).
Next, imaging....

[Ben Derman @bdermanmd]

What's the data supporting maintenance therapy in myeloma (esp. in current era)?
What happens after patients stop treatment?
Should we recommend maintenance cessation for pts w sustained MRD negativity in myeloma?
Proud of trainee Abigail Sneider for helping to put together this comprehensive review!

[Mohamad Mohty @Mohty_EBMT]

The paper of the day: a landmark publication that is bound to serve as a reference for years to come!
⁦@NatRevClinOncol⁩ ⁦@thanosdimop⁩ ⁦@COMyCongress⁩ ⁦@TheIACH⁩ ⁦@mbeksac56⁩ ⁦

[José María Cabrera @josemariacm_]

Non-ICANS neurological complications after CAR T-cell therapies: recommendations from @TheEBMT Practice Harmonisation and Guidelines Committee. Great overview by @VelascoRoser and colleagues https://t.co/8k4GSzeB7q

[EBMT @TheEBMT]

👀 Have a look at this recent publication:
📰 Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from @ECTRIMS and the EBMT ⬇️
https://t.co/K6q67JE6TC

#HCT #transplantation #patientcare #MedTwitter

[Roni Shouval @RShouval]

Salvage treatment of multi-refractory primary immune thrombocytopenia with CD19 CAR T cells - The Lancet https://t.co/cazrva7fi9

[Vincent Rajkumar @VincentRK]

Here are my Top 5 #ASH24 @ASH_hematology myeloma abstracts. #ASH24VR

Links to the full abstract. My Top 5 are based on new data, clinical impact, & methodology

Thread with countdown👇

[Muzaffar Qazilbash @Transplant_Doc]

#ASH24 Sustained MRD negativity for 3 years can guide discontinuation of Len maintenance after ASCT in MM. 92% patients remained MRD-ve 30 months after maintenance discontinuation #mmsm #bmtsm @thanosdimop https://t.co/1mGjjx3JaI

[EBMT @TheEBMT]

👀 Have a look at this recent publication in @BMTjournal:
📰 Monitoring and management of CMV and EBV after autologous haematopoietic stem cell transplantation for autoimmune diseases: a survey of the EBMT Autoimmune Diseases Working party (ADWP) ⬇️
https://t.co/uhyoE1WJJL

Authors 👤 Tobias Alexander, Manuela Badoglio, Myriam Labopin, Thomas Daikeler, Dominique Farge, Majid Kazmi, Montserrat Rovira, Elisa Roldan, John Snowden & @RaffaellaGrecoM

#HCT #CellularTherapy #BMT #transplantation #autoimmunedisease #MedTwitter

[Gloria Iacoboni @gloria_iacoboni]

Published today!💥Development and validation of the post-CAR prognostic index (PC-PI) for large B-cell lymphoma patients after CAR-T progression #lymsm #JHematolOncol

https://t.co/Kj6t1KHk19

[Hematologia ICO Hospitalet @HematICO_Hosp]

🚨 NEW PUBLICATION 🚨
@AnnaSureda5 @TheEBMT @ICO_oncologia @HematICO_Hosp et al

⬇️Check it out ⬇️

https://t.co/p8xJ8m6OQj

[raffaellagreco @RaffaellaGrecoM]

Great ADWP & CTIWP joint meeting in Milano on innovative cellular therapies and #CARTcells in #autoimmunediseases. Starting a new era together! Thanks to all the speakers, chairs and attendees. @TheEBMT @TheEBMT_CTIWP @AnnalisaRugger1 @elirolga @JKuball

[Ben Derman @bdermanmd]

What happens when patients with myeloma and sustained MRD negativity choose to discontinue maintenance? We sought to answer this question in our study MRD2STOP, out now in @BloodCancerJnl https://t.co/uHFBbT9Mhi

[Kai Rejeski @KRejeski]

Excited to share our new paper focusing on Second Primary Malignancies (SPMs) following CAR T-cell therapy out today in @CCR_AACR ! 👇

This first-in-kind meta-analysis spans 5,517 lymphoma and myeloma patients receiving a range of CAR-T products.

https://t.co/Ud0ggEaz13

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Global study of 61,725 patients with newly diagnosed myeloma undergoing upfront AHCT from 9 national/international registries shows median OS 90.2 months & PFS 36.5 months with non-relapse mortality of 1%-3%: https://t.co/DaRmus2dMF. #mmsm

[EBMT @TheEBMT]

Join us for the upcoming Educational Events 🤩 Prepare yourself for in-depth content for all of the sub-specialities within #HCT and #CellularTherapies, and meet with top professionals in the field! 🔬⚕️ Don't miss out 📅 - sign up today ⬇️ See you soon!
https://t.co/d0OlBEeJoJoin us for the upcoming Educational Events 🤩 Prepare yourself for in-depth content for all of the sub-specialities within #HCT and #CellularTherapies, and meet with top professionals in the field! 🔬⚕️ Don't miss out 📅 - sign up today ⬇️ See you soon!
https://t.co/d0OlBEeJoJoin us for the upcoming Educational Events 🤩 Prepare yourself for in-depth content for all of the sub-specialities within #HCT and #CellularTherapies, and meet with top professionals in the field! 🔬⚕️ Don't miss out 📅 - sign up today ⬇️ See you soon!
https://t.co/d0OlBEeJoJoin us for the upcoming Educational Events 🤩 Prepare yourself for in-depth content for all of the sub-specialities within #HCT and #CellularTherapies, and meet with top professionals in the field! 🔬⚕️ Don't miss out 📅 - sign up today ⬇️ See you soon!
https://t.co/d0OlBEeJoJoin us for the upcoming Educational Events 🤩 Prepare yourself for in-depth content for all of the sub-specialities within #HCT and #CellularTherapies, and meet with top professionals in the field! 🔬⚕️ Don't miss out 📅 - sign up today ⬇️ See you soon!
https://t.co/d0OlBEeJoJoin us for the upcoming Educational Events 🤩 Prepare yourself for in-depth content for all of the sub-specialities within #HCT and #CellularTherapies, and meet with top professionals in the field! 🔬⚕️ Don't miss out 📅 - sign up today ⬇️ See you soon!
https://t.co/d0OlBEeJoa

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

Discover the top-cited articles of 2024 in Transplantation and Cellular Therapy. These selections highlight key advancements in hematopoietic cell transplantation and related therapies. Access the collection here: https://t.co/Q4HbYVLhSl #HCT #GVHD #Lymsm

[Michael Makris @ProfMakris]

Excellent article in @TheLancetHaem about "normal" ranges of ferritin. It is amazing that in 2024 we are still using these in young women when we know they are wrong. They fail to identify many iron deficient women. Why are mainstream journalists not picking up the story, when it affects so many people? Article is behind a paywall. https://t.co/bVG0LR7CyZ